Matriptase and its putative role in cancer

Cellular and Molecular Life Sciences

Volumn 63, Issue 24, 2006, Pages 2968-2978

  Uhland, K ^a  

^a Curacyte Discovery GmbH   (Germany)

Author keywords

Cancer; Inhibitor; Matriptase; MT SP1; Protease

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CVS 3983; ECOTIN; MATRIPTASE; MATRIPTASE INHIBITOR; PROTEIN PRECURSOR; PROUROKINASE; SCATTER FACTOR; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE;

CANCER; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DEVELOPMENT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; TUMOR GROWTH; TUMOR PROMOTION;

ANIMALS; CELL ADHESION; ENZYME ACTIVATION; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; NEOPLASMS; PLASMINOGEN ACTIVATORS; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 33846072965     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-006-6298-x     Document Type: Review

References (104)

1. Takeuchi, T., Shuman, M. A. and Craik, C. S. (1999) Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 96, 11054-11061.
2. Tanimoto, H., Underwood, L. J., Shigemasa, K., Parmley, T. H., Wang, Y., Yan, Y., Clarke, J. and O'Brien, T. J. (1999) The matrix metalloprotease pump-1 (MMP-7, matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumour Biol. 20, 88-98.
3. Cao, J., Cai, X., Zheng, L., Geng, L., Shi, Z., Pao, C. C. and Zheng, S. (1997) Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening. J. Cancer Res. Clin. Oncol. 123, 447-451.
4. Zheng, S., Cai, X., Cao, J., Zheng, L., Geng, L., Zhang, Y., Gu, J. and Shi, Z. (1997) Screening and identification of down-regulated genes in colorectal carcinoma by subtractive hybridization: a method to identify putative tumor suppressor genes. Chin. Med. J. (Engl.) 110, 543-547.
5. Zhang, Y., Cai, X., Schlegelberger, B. and Zheng, S. (1998) Assignment of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24 → q25 by in situ hybridization. Cytogenet. Cell Genet. 83, 56-57.
6. Shi, Y. E., Torri, J., Yieh, L., Wellstein, A., Lippman, M. E. and Dickson, R. B. (1993) Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 53, 1409-1415.
7. Lin, C. Y., Wang, J. K., Torri, J., Dou, L., Sang, Q. A. and Dickson, R. B. (1997) Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells: monoclonal antibody production, isolation, and localization. J. Biol. Chem. 272, 9147-9152.
8. Takeuchi, T., Harris, J. L., Huang, W., Yan, K. W., Coughlin, S. R. and Craik, C. S. (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275, 26333-26342.
9. Lee, S. L., Dickson, R. B. and Lin, C. Y. (2000) Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720-36725.
10. Gaffney, P. J. (1977) Fibrin(-ogen) interactions with plasmin. Haemostasis 6, 2-25.
11. Liotta, L. A., Goldfarb, R. H., Brundage, R., Siegal, G. P., Terranova, V. and Garbisa, S. (1981) Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41, 4629-4636.
12. Park, J. E., Keller, G. A. and Ferrara, N. (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4, 1317-1326.
13. Remacle-Bonnet, M. M., Garrouste, F. L. and Pommier, G. J. (1997) Surface-bound plasmin induces selective proteolysis of insulin-like-growth- factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells. Int. J. Cancer 72, 835-843.
14. Odekon, L. E., Blasi, F. and Rifkin, D. B. (1994) Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J. Cell Physiol 158, 398-407.
15. Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S. and Mignatti, P. (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J. 16, 2319-2332.
16. Murphy, G., Ward, R., Gavrilovic, J. and Atkinson, S. (1992) Physiological mechanisms for metalloproteinase activation. Matrix Suppl. 1, 224-230.
17. Sidenius, N. and Blasi, F. (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22, 205-222.
18. Petersen, L. C., Lund, L. R., Nielsen, L. S., Dano, K. and Skriver, L. (1988) One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem. 263, 11189-11195.
19. Nielsen, L. S., Hansen, J. G., Skriver, L., Wilson, E. L., Kaltoft, K., Zeuthen, J. and Dano, K. (1982) Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21, 6410-6415.
20. Wun, T. C., Ossowski, L. and Reich, E. (1982) A proenzyme form of human urokinase. J. Biol. Chem. 257, 7262-7268.
21. Ichinose, A., Fujikawa, K. and Suyama, T. (1986) The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 261, 3486-3489.
22. Stack, M. S. and Johnson, D. A. (1994) Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J. Biol. Chem. 269, 9416-9419.
23. Forbs, D., Thiel, S., Stella, M. C., Sturzebecher, A., Schweinitz, A., Steinmetzer, T., Sturzebecher, J. and Uhland, K. (2005) In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int. J. Oncol. 27, 1061-1070.
24. Suzuki, M., Kobayashi, H., Kanayama, N., Saga, Y., Suzuki, M., Lin, C. Y., Dickson, R. B. and Terao, T. (2004) Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J. Biol. Chem. 279, 14899-14908.
25. Estreicher, A., Muhlhauser, J., Carpentier, J. L., Orci, L. and Vassalli, J. D. (1990) The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111, 783-792.
26. Romer, J., Lund, L. R., Eriksen, J., Pyke, C., Kristensen, P. and Dano, K. (1994) The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J. Invest. Dermatol. 102, 519-522.
27. Hung, R. J., Hsu, I., Dreiling, J. L., Lee, M. J., Williams, C. A., Oberst, M. D., Dickson, R. B. and Lin, C. Y. (2004) Assembly of adherens junctions is required for sphingosine 1-phosphate-induced matriptase accumulation and activation at mammary epithelial cell-cell contacts. Am. J. Physiol. Cell Physiol. 286, C1159-C1169.
28. Gohda, E., Tsubouchi, H., Nakayama, H., Hirono, S., Sakiyama, O., Takahashi, K., Miyazaki, H., Hashimoto, S. and Daikuhara, Y. (1988) Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J. Clin. Invest 81, 414-419.
29. Nakamura, T., Nawa, K., Ichihara, A., Kaise, N. and Nishino, T. (1987) Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett. 224, 311-316.
30. Stoker, M., Gherardi, E., Ferryman, M. and Gray, J. (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239-242.
31. Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., Fonatsch, C., Tsubouchi, H., Hishida, T., Daikuhara, Y. and. (1991) Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. USA 88, 7001-7005.
32. Naldini, L., Weidner, K. M., Vigna, E., Gaudino, G., Bardelli, A., Ponzetto, C., Narsimhan, R. P., Hartmann, G., Zarnegar, R., Michalopoulos, G. K. and. (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10, 2867-2878.
33. Zarnegar, R. and Michalopoulos, G. K. (1995) The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J. Cell Biol. 129, 1177-1180.
34. Matsumoto, K. and Nakamura, T. (1996) Emerging multipotent aspects of hepatocyte growth factor. J. Biochem. (Tokyo) 119, 591-600.
35. Trusolino, L. and Comoglio, P. M. (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2, 289-300.
36. Matsumoto, K. and Nakamura, T. (2003) NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 94, 321-327.
37. Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L. M. and Vande Woude, G. F. (2001) Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 98, 7443-7448.
38. Abounader, R., Lal, B., Luddy, C., Koe, G., Davidson, B., Rosen, E. M. and Laterra, J. (2002) In vivo targeting of SF/ HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16, 108-110.
39. Lamszus, K., Laterra, J., Westphal, M. and Rosen, E. M. (1999) Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int. J. Dev. Neurosci. 17, 517-530.
40. Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S., Risio, M., Naldini, L., Comoglio, P. M. and Michieli, P. (2004) An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest 114, 1418-1432.
41. Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L. and Comoglio, P. M. (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73.
42. Ogura, Y., Mizumoto, K., Nagai, E., Murakami, M., Inadome, N., Saimura, M., Matsumoto, K., Nakamura, T., Maemondo, M., Nukiwa, T. and Tanaka, M. (2006) Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther. 13, 520-529.
43. Kim, K. J., Wang, L., Su, Y. C., Gillespie, G. Y., Salhotra, A., Lal, B. and Laterra, J. (2006) Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 12, 1292-1298.
44. Hartmann, G., Naldini, L., Weidner, K. M., Sachs, M., Vigna, E., Comoglio, P. M. and Birchmeier, W. (1992) A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc. Natl. Acad. Sci. USA 89, 11574-11578.
45. Lokker, N. A., Mark, M. R., Luis, E. A., Bennett, G. L., Robbins, K. A., Baker, J. B. and Godowski, P. J. (1992) Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO 111, 2503-2510.
46. Ferracini, R., Di Renzo, M. F., Scotlandi, K., Baldini, N., Olivero, M., Lollini, P., Cremona, O., Campanacci, M. and Comoglio, P. M. (1995) The Met/HGF receptor is overexpressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-749.
47. Olivero, M., Rizzo, M., Madeddu, R., Casadio, C., Pennacchietti, S., Nicotra, M. R., Prat, M., Maggi, G., Arena, N., Natali, P. G., Comoglio, P. M. and Di Renzo, M. F. (1996) Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br. J. Cancer 74, 1862-1868.
48. Kataoka, H., Hamasuna, R., Itoh, H., Kitamura, N. and Koono, M. (2000) Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res. 60, 6148-6159.
49. Mars, W. M., Liu, M. L., Kitson, R. P., Goldfarb, R. H., Gabauer, M. K. and Michalopoulos, G. K. (1995) Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration. Hepatology 21, 1695-1701.
50. Miyazawa, K., Shimomura, T., Kitamura, A., Kondo, J., Morimoto, Y. and Kitamura, N. (1993) Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J. Biol. Chem. 268, 10024-10028.
51. Miyazawa, K., Shimomura, T., Naka, D. and Kitamura, N. (1994) Proteolytic activation of hepatocyte growth factor in response to tissue injury. J. Biol. Chem. 269, 8966-8970.
52. Miyazawa, K., Shimomura, T. and Kitamura, N. (1996) Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J. Biol. Chem. 271, 3615-3618.
53. Shimomura, T., Miyazawa, K., Komiyama, Y., Hiraoka, H., Naka, D., Morimoto, Y. and Kitamura, N. (1995) Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur. J. Biochem. 229, 257-261.
54. Peek, M., Moran, P., Mendoza, N., Wickramasinghe, D. and Kirchhofer, D. (2002) Unusual proteolytic activation of prohepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J. Biol. Chem. 277, 47804-47809.
55. Kim, M. G., Chen, C., Lyu, M. S., Cho, E. G., Park, D., Kozak, C. and Schwartz, R. H. (1999) Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 49, 420-428.
56. List, K., Szabo, R., Molinolo, A., Sriuranpong, V., Redeye, V., Murdock, T., Burke, B., Nielsen, B. S., Gutkind, J. S. and Bugge, T. H. (2005) Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 19, 1934-1950.
57. Noonan, F. P., Otsuka, T., Bang, S., Anver, M. R. and Merlino, G. (2000) Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. Cancer Res. 60, 3738-3743.
58. Comoglio, P. M. and Trusolino, L. (2005) Cancer: the matrix is now in control. Nat. Med. 11, 1156-1159.
59. Kang, J. Y., Dolled-Filhart, M., Ocal, I. T., Singh, B., Lin, C. Y., Dickson, R. B., Rimm, D. L. and Camp, R. L. (2003) Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63, 1101-1105.
60. Satomi, S., Yamasaki, Y., Tsuzuki, S., Hitomi, Y., Iwanaga, T. and Fushiki, T. (2001) A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem. Biophys. Res. Commun. 287, 995-1002.
61. Sun, L. F., Zheng, S., Shi, Y., Fang, X. M., Ge, W. T. and Ding, K. F. (2004) SNC19/ST14 gene transfection and expression influence the biological behavior of colorectal cancer cells (in Chinese). Zhonghua Yi. Xue. Za Zhi. 84, 843-848.
62. Ding, K. F., Sun, L. F., Ge, W. T., Hu, H. G., Zhang, S. Z. and Zheng, S. (2005) Effect of SNC19/ST14 gene overexpression on invasion of colorectal cancer cells. World J. Gastroenterol. 11, 5651-5654.
63. Ahmed, S., Jin, X., Yagi, M., Yasuda, C., Sato, Y., Higashi, S., Lin, C. Y., Dickson, R. B. and Miyazaki, K. (2006) Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J. 273, 615-627.
64. Akaogi, K., Okabe, Y., Sato, J., Nagashima, Y., Yasumitsu, H., Sugahara, K. and Miyazaki, K. (1996) Specific accumulation of tumor-derived adhesion factor in tumor blood vessels and in capillary tube-like structures of cultured vascular endothelial cells. Proc. Natl. Acad. Sci. USA 93, 8384-8389.
65. Adachi, Y., Itoh, F., Yamamoto, H., Arimura, Y., Kikkawa-Okabe, Y., Miyazaki, K., Carbone, D. P. and Imai, K. (2001) Expression of angiomodulin (tumor-derived adhesion factor/ mac25) in invading tumor cells correlates with poor prognosis in human colorectal cancer. Int. J. Cancer 95, 216-222.
66. Ahmed, S., Yamamoto, K., Sato, Y., Ogawa, T., Herrmann, A., Higashi, S. and Miyazaki, K. (2003) Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/mac25) modulates its biological activity. Biochem. Biophys. Res. Commun. 310, 612-618.
67. Sato, J., Hasegawa, S., Akaogi, K., Yasumitsu, H., Yamada, S., Sugahara, K. and Miyazaki, K. (1999) Identification of cell-binding site of angiomodulin (AGM/TAF/Mac25) that interacts with heparan sulfates on cell surface. J. Cell Biochem. 75, 187-195.
68. Sprenger, C. C., Vail, M. E., Evans, K., Simurdak, J. and Plymate, S. R. (2002) Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene 21, 140-147.
69. Mutaguchi, K., Yasumoto, H., Mita, K., Matsubara, A., Shiina, H., Igawa, M., Dahiya, R. and Usui, T. (2003) Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res. 63, 7717-7723.
70. Wilson, H. M., Birnbaum, R. S., Foot, M., Quinn, L. S. and Swisshelm, K. (2002) Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 13, 205-213.
71. List, K., Haudenschild, C. C., Szabo, R., Chen, W., Wahl, S. M., Swaim, W., Engelholm, L. H., Behrendt, N. and Bugge, T. H. (2002) Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21, 3765-3779.
72. List, K., Szabo, R., Wertz, P. W., Segre, J., Haudenschild, C. C., Kim, S. Y. and Bugge, T. H. (2003) Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J. Cell Biol. 163, 901-910.
73. Pearton, D. J., Dale, B. A. and Presland, R. B. (2002) Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution. J. Invest. Dermatol. 119, 661-669.
74. List, K., Szabo, R., Molinolo, A., Nielsen, B. S. and Bugge, T. H. (2006) Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am. J. Pathol. 168, 1513-1525.
75. Ihara, S., Miyoshi, E., Ko, J. H., Murata, K., Nakahara, S., Honke, K., Dickson, R. B., Lin, C. Y. and Taniguchi, N. (2002) Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J. Biol. Chem. 277, 16960-16967.
76. Lin, C. Y., Anders, J., Johnson, M., Sang, Q. A. and Dickson, R. B. (1999) Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 274, 18231-18236.
77. Oberst, M. D., Williams, C. A., Dickson, R. B., Johnson, M. D. and Lin, C. Y. (2003) The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J. Biol. Chem. 278, 26773-26779.
78. Oberst, M. D., Singh, B., Ozdemirli, M., Dickson, R. B., Johnson, M. D. and Lin, C. Y. (2003) Characterization of matriptase expression in normal human tissues. J. Histochem. Cytochem. 51, 1017-1025.
79. Takeuchi, T., Shuman, M. A. and Craik, C. S. (1999) Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 96, 11054-11061.
80. Benaud, C., Dickson, R. B. and Lin, C. Y. (2001) Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur. J. Biochem. 268, 1439-1447.
81. Benaud, C., Oberst, M., Hobson, J. P., Spiegel, S., Dickson, R. B. and Lin, C. Y. (2002) Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J. Biol. Chem. 277, 10539-10546.
82. Benaud, C. M., Oberst, M., Dickson, R. B. and Lin, C. Y. (2002) Deregulated activation of matriptase in breast cancer cells. Clin. Exp. Metastasis 19, 639-649.
83. Oberst, M. D., Chen, L. Y., Kiyomiya, K., Williams, C. A., Lee, M. S., Johnson, M. D., Dickson, R. B. and Lin, C. Y. (2005) HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am. J. Physiol. Cell Physiol. 289, C462-C470.
84. Oberst, M. D., Johnson, M. D., Dickson, R. B., Lin, C. Y., Singh, B., Stewart, M., Williams, A., al Nafussi, A., Smyth, J. F., Gabra, H. and Sellar, G. C. (2002) Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8, 1101-1107.
85. Martin, D. B., Gifford, D. R., Wright, M. E., Keller, A., Yi, E., Goodlett, D. R., Aebersold, R. and Nelson, P. S. (2004) Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res. 64, 347-355.
86. Kiyomiya, K., Lee, M. S., Tseng, I. C., Zuo, H., Barndt, R. J., Johnson, M. D., Dickson, R. B. and Lin, C. Y. (2006) Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am. J. Physiol. Cell Physiol. 291, C40-C49.
87. Dennis, J. W., Granovsky, M. and Warren, C. E. (1999) Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473, 21-34.
88. Granovsky, M., Fata, J., Pawling, J., Muller, W. J., Khokha, R. and Dennis, J. W. (2000) Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med. 6, 306-312.
89. Taniguchi, N., Ihara, S., Saito, T., Miyoshi, E., Ikeda, Y. and Honke, K. (2001) Implication of GnT-V in cancer metastasis: a glycomic approach for identification of a target protein and its unique function as an angiogenic cofactor. Glycoconj. J. 18, 859-865.
90. Ono, M. and Hakomori, S. (2004) Glycosylation defining cancer cell motility and invasiveness. Glycoconj. J. 20, 71-78.
91. Siddiqui, S. F., Pawelek, J., Handerson, T., Lin, C. Y., Dickson, R. B., Rimm, D. L. and Camp, R. L. (2005) Coexpression of beta1,6-N- acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome. Cancer Epidemiol. Biomarkers Prev. 14, 2517-2523.
92. Takeuchi, T., Shuman, M. A. and Craik, C. S. (1999) Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 96, 11054-11061.
93. Galkin, A. V., Mullen, L., Fox, W. D., Brown, J., Duncan, D., Moreno, O., Madison, E. L. and Agus, D. B. (2004) CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 61, 228-235.
94. Steinmetzer, T., Schweinitz, A., Stürzebecher, A., Dönnecke, D., Uhland, K., Schuster, O., Friedrich, R., Than, M. E., Bode, W. and Stürzebecher, J. (in press) Secondary amides of sulfonylated 3-aminophenylalanine - new potent and selective inhibitors of matriptase. J. Med. Chem.
95. Suzuki, M., Kobayashi, H., Tanaka, Y., Hirashima, Y., Kanayama, N., Takei, Y., Saga, Y., Suzuki, M., Itoh, H. and Terao, T. (2003) Bikunin target genes in ovarian cancer cells identified by microarray analysis. J. Biol. Chem. 278, 14640-14646.
96. Santin, A. D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J. J., O'Brien, T. J., Tian, E., Cannon, M. J., Shaughnessy, J. Jr, and Pecorelli, S. (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 112, 14-25.
97. Jin, J. S., Hsieh, D. S., Loh, S. H., Chen, A., Yao, C. W. and Yen, C. Y. (2006) Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod. Pathol. 19, 447-452.
98. Riddick, A. C., Shukla, C. J., Pennington, C. J., Bass, R., Nuttall, R. K., Hogan, A., Sethia, K. K., Ellis, V., Collins, A. T., Maitland, N. J., Ball, R. Y. and Edwards, D. R. (2005) Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer 92, 2171-2180.
99. Saleem, M., Adhami, V. M., Zhong, W., Longley, B. J., Lin, C. Y., Dickson, R. B., Reagan-Shaw, S., Jarrard, D. F. and Mukhtar, H. (2006) A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol. Biomarkers Prev. 15, 217-227.
100. Hoang, C. D., D'Cunha, J., Kratzke, M. G., Casmey, C. E., Frizelle, S. P., Maddaus, M. A. and Kratzke, R. A. (2004) Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125, 1843-1852.
101. Santin, A. D., Cane', S., Bellone, S., Bignotti, E., Palmieri, M., Las Casas, L. E., Anfossi, S., Roman, J. J., O'Brien, T. and Pecorelli, S. (2003) The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 98, 1898-1904.
102. Lee, J. W., Yong, S. S., Choi, J. J., Lee, S. J., Kim, B. G., Park, C. S., Lee, J. H., Lin, C. Y., Dickson, R. B. and Bae, D. S. (2005) Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum. Pathol. 36, 626-633.
103. Jarzab, B., Wiench, M., Fujarewicz, K., Simek, K., Jarzab, M., Oczko-Wojciechowska, M., Wloch, J., Czarniecka, A., Chmielik, E., Lange, D., Pawlaczek, A., Szpak, S., Gubala, E. and Swierniak, A. (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 65, 1587-1597.
104. Ge, W., Hu, H., Ding, K., Sun, L. and Zheng, S. (2006) Protein interaction analysis of ST14 domains and their point and deletion mutants. J. Biol. Chem. 281, 7406-7412.